Summary of efficacy (liso-cel–treated efficacy analysis set)
| . | Liso-cel–treated efficacy analysis set (n = 61) . |
|---|---|
| ORR (CR + PR), n (%) [95% CI]∗ | 49 (80) [68-89] |
| CR rate, n (%) [95% CI]∗ | 33 (54) [41-67] |
| BOR, n (%) | |
| CR | 33 (54) |
| PR | 16 (26) |
| SD | 3 (5) |
| PD | 8 (13) |
| NE | 1 (2) |
| DOR | |
| Median (95% CI), mo† | 23.3 (6.2 to NR) |
| Continued response at 12 months, % (95% CI)† | 55 (40-68) |
| Continued response at 18 months, % (95% CI)† | 53 (37-66) |
| Median follow-up (95% CI), mo‡ | 23.1 (22.9-23.3) |
| PFS | |
| Median (95% CI), mo† | 9.0 (4.2 to NR) |
| 12-month PFS rate, % (95% CI)† | 47 (33-59) |
| 18-month PFS rate, % (95% CI)† | 43 (30-55) |
| Median follow-up (95% CI), mo‡ | 24.0 (23.8-24.2) |
| EFS | |
| Median (95% CI), mo† | 7.2 (3.2-24.3) |
| 12-month EFS rate, % (95% CI)† | 44 (31-56) |
| 18-month EFS rate, % (95% CI)† | 40 (28-52) |
| Median follow-up (95% CI), mo‡ | 24.0 (23.8-24.2) |
| OS | |
| Median (95% CI), mo† | NR (16.3 to NR) |
| 12-month OS rate, % (95% CI)† | 68 (55-78) |
| 18-month OS rate, % (95% CI)† | 59 (45-70) |
| Median follow-up (95% CI), mo‡ | 24.3 (24.0-24.8) |
| . | Liso-cel–treated efficacy analysis set (n = 61) . |
|---|---|
| ORR (CR + PR), n (%) [95% CI]∗ | 49 (80) [68-89] |
| CR rate, n (%) [95% CI]∗ | 33 (54) [41-67] |
| BOR, n (%) | |
| CR | 33 (54) |
| PR | 16 (26) |
| SD | 3 (5) |
| PD | 8 (13) |
| NE | 1 (2) |
| DOR | |
| Median (95% CI), mo† | 23.3 (6.2 to NR) |
| Continued response at 12 months, % (95% CI)† | 55 (40-68) |
| Continued response at 18 months, % (95% CI)† | 53 (37-66) |
| Median follow-up (95% CI), mo‡ | 23.1 (22.9-23.3) |
| PFS | |
| Median (95% CI), mo† | 9.0 (4.2 to NR) |
| 12-month PFS rate, % (95% CI)† | 47 (33-59) |
| 18-month PFS rate, % (95% CI)† | 43 (30-55) |
| Median follow-up (95% CI), mo‡ | 24.0 (23.8-24.2) |
| EFS | |
| Median (95% CI), mo† | 7.2 (3.2-24.3) |
| 12-month EFS rate, % (95% CI)† | 44 (31-56) |
| 18-month EFS rate, % (95% CI)† | 40 (28-52) |
| Median follow-up (95% CI), mo‡ | 24.0 (23.8-24.2) |
| OS | |
| Median (95% CI), mo† | NR (16.3 to NR) |
| 12-month OS rate, % (95% CI)† | 68 (55-78) |
| 18-month OS rate, % (95% CI)† | 59 (45-70) |
| Median follow-up (95% CI), mo‡ | 24.3 (24.0-24.8) |